- Home
- SCNI vs ONCO Comparison
SCNI vs ONCO Comparison
Compare SCNI & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNI
- ONCO
- Stock Information
- Founded
- SCNI 2003
- ONCO 2018
- Country
- SCNI Israel
- ONCO United States
- Employees
- SCNI N/A
- ONCO N/A
- Industry
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- SCNI Health Care
- ONCO Health Care
- Exchange
- SCNI Nasdaq
- ONCO Nasdaq
- Market Cap
- SCNI 1.5M
- ONCO 1.8M
- IPO Year
- SCNI N/A
- ONCO 2022
- Fundamental
- Price
- SCNI $1.57
- ONCO $2.95
- Analyst Decision
- SCNI
- ONCO
- Analyst Count
- SCNI 0
- ONCO 0
- Target Price
- SCNI N/A
- ONCO N/A
- AVG Volume (30 Days)
- SCNI 324.3K
- ONCO 106.7K
- Earning Date
- SCNI 09-16-2025
- ONCO 08-14-2025
- Dividend Yield
- SCNI N/A
- ONCO N/A
- EPS Growth
- SCNI N/A
- ONCO N/A
- EPS
- SCNI N/A
- ONCO N/A
- Revenue
- SCNI $1,147,000.00
- ONCO $1,326,959.00
- Revenue This Year
- SCNI N/A
- ONCO N/A
- Revenue Next Year
- SCNI N/A
- ONCO N/A
- P/E Ratio
- SCNI $4.25
- ONCO N/A
- Revenue Growth
- SCNI N/A
- ONCO N/A
- 52 Week Low
- SCNI $1.40
- ONCO $2.61
- 52 Week High
- SCNI $6.18
- ONCO $552.50
- Technical
- Relative Strength Index (RSI)
- SCNI 45.14
- ONCO 43.21
- Support Level
- SCNI $1.46
- ONCO $2.82
- Resistance Level
- SCNI $1.68
- ONCO $3.20
- Average True Range (ATR)
- SCNI 0.12
- ONCO 0.19
- MACD
- SCNI 0.03
- ONCO 0.06
- Stochastic Oscillator
- SCNI 33.33
- ONCO 56.90
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.